Bayer and Ural Pharmaceutical Cluster representatives met to discuss the joint production of pharmaceuticals in Russia.

It was announced that the first stage of Bayer and Ural Pharmaceutical Cluster’s cooperation would consist in full-cycle production of Bayer’s medicines using the facilities of Medsintez Plant (one of Cluster’s residents) in Novouralsk. The production will make use of on both the plant’s existing facilities and the new production sites the Cluster is planning to put up.

At the moment, the medicines that are expected to be manufactured in Russia are antibiotics Avelox and Ciprobay and the medication meant for diagnostic visualization and treatment of neurological disorders called Nimotop.

On March 12-16, a group of delegates visited the plant, including representatives of Bayer Product Supply, Bayer Technology Services, and Quality Assurance Departments and those from the Bayer’s Russian representation; these executives will be directly responsible for designing the new pharmaceutical production site.

The joint production will probably begin in 2014.